Biotech SF

San Francisco Bay Area biotech stories.

Showing posts with label Tarceva. Show all posts

Friday, January 28, 2011

Success with Genentech cancer drug Tarceva could end study early

Posted by Unknown at 1:25 PM No comments:

Email This BlogThis!Share to X Share to Facebook Share to Pinterest

Labels: Genentech, OSI Pharmaceuticals, Tarceva

Older Posts Home

Subscribe to: Posts (Atom)

Some of my favorite stories.

• "The fight of his life" (2007)

Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)

Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)

Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)

Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.

All he needs now is $20 million.

Subscribe To

Posts

Atom

Posts

All Comments

Atom

All Comments

Blog Archive

▼ 2012 (486)
- ▼ November (18)
- ► October (25)
- ► September (56)
- ► August (56)
- ► July (64)
- ► June (26)
- ► May (40)
- ► April (39)
- ► March (31)
- ► February (74)
- ► January (57)

► 2011 (772)
- ► December (54)
- ► November (40)
- ► October (65)
- ► September (74)
- ► August (48)
- ► July (44)
- ► June (60)
- ► May (70)
- ► April (80)
- ► March (81)
- ► February (77)
- ► January (79)

► 2010 (59)
- ► December (42)
- ► November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.

Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's

Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

"Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)